The short version of anti-doping testing fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-31. Anything still debated is marked as such rather than presented as settled.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
== Differential diagnosis == Other disorders that may be accompanied by chorea include benign hereditary chorea, bilateral striatal necrosis, abetalipoproteinemia, ataxia–telangiectasia, biotin-thiamine-responsive basal ganglia disease (BTBGD), Fahr disease, familial dyskinesia–facial myokymia (Bird–Raskind syndrome) due to an ADCY5 gene mutation, glutaric aciduria, Lesch–Nyhan syndrome, mitochondrial disorders, Huntington's disease, Wilson disease, hyperthyroidism, lupus erythematosus, pregnancy (chorea gravidarum), drug intoxication and side effects of certain anticonvulsants (e.g. phenytoin) or psychotropic agents. Although some of these can similarly present in an acute way, there will typically be other neurological signs (such as ataxia or cognitive impairment), or other disease manifestations, or positive family history, which will help distinguish between them.
== Nomenclature == Endogenous: somatocrinin somatoliberin growth hormone–releasing hormone (GHRH or GH-RH; HGNC symbol is GHRH) growth hormone–releasing factor (GHRF or GRF) somatotropin-releasing hormone (SRH) somatotropin-releasing factor (SRF) Pharmaceutical: somatorelin (INN)
Clark Oderth Olofsson (later known as Daniel Demuynck; 1 February 1947 – 24 June 2025) was a Swedish criminal. He received sentences for attempted murder, assault, robbery and dealing narcotics and spent more than half of his life in prison. Olofsson was often referred to as Sweden's first "celebrity gangster". Olofsson faced a tumultuous childhood marked by familial challenges. Growing up amidst extensive alcohol problems, he endured the departure of his father and his mother's subsequent illness, which led to the placement of Olofsson and his two younger sisters in foster care. Determined to escape an unhappy foster family, Olofsson enrolled in a sailors' school then forged his mother's signature at the age of 15 to be able to embark on the ship Ballade, he sailed around the world, gaining a unique perspective between Japan and South America. Returning home at 15, Olofsson reunited with his mother, who had regained stability. Despite earlier adversities, the family settled in Gothenburg, where Olofsson's journey took a criminal turn. Convicted for various offenses in the 1960s, including burglary and assault, Olofsson gained notoriety for his involvement in the killing of a police officer during a robbery. Multiple prison escapes characterized his criminal career, with notable incidents like the Norrmalmstorg robbery, giving rise to the term "Stockholm syndrome". Throughout the 1970s and 1980s, Olofsson continued a pattern of escapes, criminal activities, and imprisonments, marked by a marriage in Kumla Prison.
== Relationship between atomic and molecular masses == Similar definitions apply to molecules. One can calculate the molecular mass of a compound by adding the atomic masses (not the standard atomic weights) of its constituent atoms. Conversely, the molar mass is usually computed from the standard atomic weights (not the atomic or nuclide masses). Thus, molecular mass and molar mass differ slightly in numerical value and represent different concepts. Molecular mass is the mass of a molecule, which is the sum of its constituent atomic masses. Molar mass is an average of the masses of the constituent molecules in a chemically pure but isotopically heterogeneous ensemble. In both cases, the multiplicity of the atoms (the number of times it occurs) must be taken into account, usually by multiplication of each unique mass by its multiplicity.
Early grocery stores were "austere" and tiny by modern standards, with as few as 450 items. Shopping for groceries often involved trips to multiple specialty shops, such as a greengrocer, butcher, bakery, fishmonger and dry goods store, in addition to a general store. Milk and other items of short shelf life were delivered by a milkman. These small retailers were the final links in a "long and tortuous food chain," as most of them were far too small to deal directly with most of the persons who actually harvested, processed, and distributed all that food. During the 1920s, the highly inefficient nature of the American food distribution system meant that the "average urban family spent fully one-third of its budget on food". One of the most important defining features of the modern supermarket is cheap food. The vast abundance of cheap, wholesome food which modern consumers take for granted today was simply unimaginable before the middle of the 20th century, to the point that the first American supermarket customers in the 1930s were overcome with emotion at the sight of so much cheap food. Before the 20th century, food was neither cheap, nor wholesome, nor abundant. For example, in 1812, almost 90 percent of Americans worked in food production, and they struggled to stay alive on food which was often scarce, of poor quality, and riddled with diseases which could and did often kill them.
Sources: en.wikipedia.org
August 15, 2009: Portugal Portugal leaves recession after three consecutive quarters of negative growth having its GDP recover by 0.3% in the second quarter of 2009. According to the latest estimates by the Bank of Portugal, Portuguese GDP should fall around 3.5% in 2009, which is the worst figure for the country since 1975.
The evolutionary adaptation from primary to secondary vascular tissues demonstrates how this monocot developed its tree-like form, combining water conservation through its dense crown with structural stability from its specialized stem growth. These features collectively enable the species to thrive in challenging high-altitude, arid conditions where few other trees can survive.
Dehydrogenases oxidize a substrate by transferring hydrogen to an electron acceptor, common electron acceptors being NAD+ or FAD. This would be considered an oxidation of the substrate, in which the substrate either loses hydrogen atoms or gains an oxygen atom (from water). The name "dehydrogenase" is based on the idea that it facilitates the removal (de-) of hydrogen (-hydrogen-) and is an enzyme (-ase). Dehydrogenase reactions come most commonly in two forms: the transfer of a hydride and release of a proton (often with water as a second reactant), and the transfer of two hydrogens.
=== Protein tags === BCCP (Biotin Carboxyl Carrier Protein), a protein domain biotinylated by BirA enabling recognition by streptavidin BromoTag, a "bump-and-hole" mutated version of the second bromodomain of Brd4, Brd4-BD2 L387A, that can be highly selectively bound by tag-specific PROTAC degrader AGB1 to form a ternary complex between the "BromoTagged" protein and the E3 ligase VHL, leading to ubiquitination of the tagged protein and its subsequent rapid and effective proteasomal degradation in cells. FAST (Fluorescence-Activating and absorption-Shifting Tag), a mutated photoactive yellow protein (PYP) that reversibly binds cognate fluorogenic ligands CL7-tag, an engineered variant of Colicin E7 that has a strong binding affinity and specificity for immobilized Immunity Protein 7 (Im7). Glutathione-S-transferase-tag, a protein which binds to immobilized glutathione Green fluorescent protein-tag, a protein which is spontaneously fluorescent and can be bound by nanobodies HaloTag, a mutated bacterial haloalkane dehalogenase that covalently attaches to haloalkane substrates SNAP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylguanine derivatives CLIP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylcytosine derivatives HUH-tag, a sequence-specific single-stranded DNA binding protein that covalently binds to its target sequence Maltose binding protein-tag, a protein which binds to amylose agarose Nus-tag Thioredoxin-tag Fc-tag, derived from immunoglobulin Fc domain, allow dimerization and solubilization.
Silica nanoparticles- Silica nanoparticles can be classified into solid, non-porous, and mesoporous. They have large surface are, hydrophilic surface, and chemical and physical stabilities. Silica nanoparticles are made by the use of the Stöber process. Which is the hydrolysis of silyl ethers such as tetraethyl silicate into silanols (Si-OH) using ammonia in a mixture of water and alcohol followed by the condensation of silanols into 50–2000 nm silica particles. The size of the particle can be controlled by varying the concentration of silyl ether and alcohol or the micro emulsion method. Mesoporous silica nanoparticles are synthesized by the sol-gel process. They have pores that range in diameter from 2 nm to 50 nm. They are synthesized in a water-based solution in the presence of a base catalyst and a pore forming agent known as a surfactant. Surfactants are molecules that present the particularity to have a hydrophobic tail (alkyl chain) and a hydrophilic head (charged group, such as a quaternary amine for example). As these surfactants are added to a water-based solution, they will coordinate to form micelles with increasing concentration in order to stabilize the hydrophobic tails. Varying the pH of the solution and composition of the solvents, and the addition of certain swelling agents can control the pore size. Their hydrophilic surface is what makes silica nanoparticles so important and allows them to carry out functions such as drug and gene delivery, bio imaging and therapy.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.